Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328561 · ClinicalTrials.gov registry record
Oxytocin and Arginine Vasopressin in Pain Relief
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- 167
- Enrollment target
NCT01328561: Clinical Trial study, sponsored by National Institute of Mental Health (NIMH).
NCT01328561 is a clinical trial that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 167 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01328561 was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- 167 participants
- Enrollment target
Study Summary
Background: \- Oxytocin, a substance produced mostly in the brain, plays a role in influencing social interactions and reactions to stress, and may be related to pain. Arginine vasopressin, a hormone that regulates water, sugar, and salt in the blood, influences hostile behaviors and reactions to stress, and may also be related to pain. Researchers are interested in investigating both substances and their relationship to pain in healthy volunteers. Objectives: \- To evaluate the effects of oxytocin and arginine vasopressin on pain in healthy volunteers. Eligibility: \- Healthy volunteers between 18 and 55 years of age. Design: * This study involves two 2-hour testing sessions held 1 day apart. Each session includes the administration of oxytocin, arginine vasopressin, or placebo (a nonactive substance), or no drug. The drugs and the placebo will be given by a nasal spray. * At the first visit, participants will provide blood and saliva samples to measure hormone levels, and will be asked to fill out questionnaires about some psychological factors such as anxiety and empathy. Participants will then have an assessment of their sensitivity to pain, consisting of a brief electrical stimulation that lasts less than 1 second. After the pain assessment, participants will receive oxytocin, arginine vasopressin, placebo, or no drug at all, and will be monitored to provide baseline information. Participants will then have another pain sensitivity test and will complete the questionnaires again, and provide another saliva sample. * At the second visit, participants will provide another saliva sample; receive oxytocin, arginine vasopressin, placebo, or no drug at all; and have tests of pain sensitivity and a pain-relieving procedure. During the pain-relieving procedure, participants will receive brief, moderately painful electrical shocks on the back of the nondominant hand and a low-level electrical stimulation on the middle finger that counteracts or reduces the pain f
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2011-03-17 |
| Est. Completion | 2015-03-04 |
Why NCT01328561 stopped before completion
NCT01328561 is an observational study that tracks outcomes without assigning an intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01328561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01328561 about?
NCT01328561 is a clinical study titled "Oxytocin and Arginine Vasopressin in Pain Relief". Background: \- Oxytocin, a substance produced mostly in the brain, plays a role in influencing social interactions and reactions to stress, and may be related to pain. Arginine vasopressin, a hormone that regulates water, sugar, and salt in the blood, influences hostile behaviors and reactions to s...
What is the current status of trial NCT01328561?
This trial is currently terminated. The enrollment target is 167 participants. The study started on 2011-03-17. Estimated completion is 2015-03-04.
Who is sponsoring clinical trial NCT01328561?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI